Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 38 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Minimal Change Disease Clear all

Conditions: Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
Interventions: Interview; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 2 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions: Kidney Biopsy; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: Up to 80 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 39
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Conditions: Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions: Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis; Biological · Procedure · Other
Lead sponsor: Sumithira Vasu; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy; Radiation · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Interventions: frexalimab, brivekimig, rilzabrutinib, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 15 more

Conditions: Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Interventions: D-Galactose; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
Interventions: GFB-887, Placebo; Drug
Lead sponsor: Goldfinch Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 74
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more

Conditions: Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions: Transcutaneous auricular vagus nerve stimulation, Sham device; Device
Lead sponsor: Northwell Health; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Idiopathic Nephrotic Syndrome
Interventions: Standard of Care, UrApp; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Portland, Oregon

Conditions: Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions: VB119; Drug
Lead sponsor: Tenet Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Albany, New York

Conditions: Leukemia, Acute Lymphoblastic
Interventions: CART 19; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glomerular Disease
Interventions: Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks; Dietary Supplement
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 30 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more

Conditions: Colon Adenocarcinoma, Colorectal Cancer
Interventions: TAS-102, Irinotecan, Standard Treatment, Signatera MRD ctDNA Assay; Drug · Combination Product · Diagnostic Test
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 23 Years to 79 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Princeton, New Jersey

Search by objective public record fields.

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

Nephrotic Syndrome Study Network

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

taVNS for FRNS in Children

UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL

Vitamin D Supplementation in Glomerular Disease

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)